Zenyaku Ends Japan Alliance With Anthera
This article was originally published in PharmAsia News
Executive Summary
Anthera's development partner in Japan for autoimmune disorder drug blisibimod has served a termination notice for the late 2014 deal, but the US firm says the impact could in fact be positive.